NCT05355051View on ClinicalTrials.gov

A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

October 5, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Hodgkin's Lymphoma

Interventions

DRUG

Azacytidine

Given by Vein (IV)

DRUG

Pembrolizumab

Given by Vein (IV)

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER